Werewolf Therapeutics (HOWL) presents a deeply distressed liquidation profile as of March 31, 2026. MFFAIS reports a liquidation value of negative $31.4M across all three methodologies (CLV, LLV, OLV), consistent with what the balance sheet produces under standard haircut assumptions. Total assets of $58.0M are dominated by cash and cash equivalents of $46.5M (100% recoverable) plus restricted cash of $0.9M, yielding approximately $47.4M in liquid asset recovery. Remaining assets include prepaid/other current of $2.3M (haircut to ~$2.1M), PP&E net of $4.3M (haircut to ~$2.1-3.0M at 50-70%), and operating lease ROU asset of $5.0M (zero recovery under liquidation). Against this, total liabilities of $45.8M must be settled at face value: current notes payable of $28.8M (K2HV term loan, classified current), operating lease liabilities of $8.8M ($1.6M current, $7.2M noncurrent), accounts payable of $3.6M, accrued liabilities of $4.5M, accrued professional fees of $1.7M, and a derivative liability (conversion option) of $0.085M. The lease liability stack ($8.8M total at face) is particularly punishing: the ROU asset recovers zero in liquidation while the liability remains in full. The K2HV term loan ($32.1M gross, $28.8M net of discount per current classification) is the single largest liability item and accelerates the recovery deficit. Maturity schedule shows $9.6M due remainder of 2025, $14.4M in next twelve months, and $8.1M in year two — the entire balance callable or maturing within approximately 18 months, eliminating any going-concern restructuring buffer under a wind-down scenario. The Jazz Pharmaceuticals collaboration agreement was terminated in May 2026 (post period-end), eliminating any residual deferred revenue or future milestone cash flows from that arrangement. The company implemented a ~64% RIF in February 2026, reducing to 14 employees as of March 31, 2026, and is actively pursuing strategic alternatives. A Nasdaq minimum bid deficiency notice was received February 4, 2026, with a compliance deadline of August 3, 2026. Accumulated deficit stands at $488.9M. The filing discusses restructuring charges of $4.3M recognized in the quarter (expected total of $6.4M) in MD&A but the restructuring reserve remaining at period-end is only $0.4M, indicating most cash severance was already paid ($4.0M cash outflow tagged). Filing does not separately disclose any cash runway estimate or going-concern assessment language in the excerpted portions, though the operational posture — no revenue, 14 employees, strategic alternatives process — is consistent with a company in pre-wind-down mode. Net equity of $12.2M on the face of the balance sheet overstates true liquidation recovery given ROU asset impairment and the lease liability face-value asymmetry.
▼ Community Notes